Attys Seek $113M In Fees From Glumetza Buyers' $454M Deal

By Dave Simpson (December 2, 2021, 6:52 PM EST) -- A class of direct Glumetza buyers who scored $454 million in settlements that will end several claims that drugmakers plotted to delay the generic version of the blockbuster diabetes drug asked a California federal court Wednesday to award plaintiffs' attorneys $112.8 million in fees and $2.4 million in costs.

The co-lead attorneys from Hilliard Shadowen LLP, Hagens Berman Sobol Shapiro LLP and Sperling & Slater PC acknowledged their "self-interested bias" and that fee bids often "bend toward self-aggrandizing, one-sided brags" but said that in their request for 25% of the settlement fund they aspire to be "honest brokers."

"Class counsel found...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!